A multidisciplinary approach to the clinical management of Prader-Willi syndrome
- PMID: 30697974
- PMCID: PMC6418440
- DOI: 10.1002/mgg3.514
A multidisciplinary approach to the clinical management of Prader-Willi syndrome
Abstract
Background: Prader-Willi syndrome (PWS) is a complex neuroendocrine disorder affecting approximately 1/15,000-1/30,000 people. Unmet medical needs of individuals with PWS make it a rare disease that models the importance of multidisciplinary approaches to care with collaboration between academic centers, medical homes, industry, and parent organizations. Multidisciplinary clinics support comprehensive, patient-centered care for individuals with complex genetic disorders and their families. Value comes from improved communication and focuses on quality family-centered care.
Methods: Interviews with medical professionals, scientists, managed care experts, parents, and individuals with PWS were conducted from July 1 to December 1, 2016. Review of the literature was used to provide support.
Results: Data are presented based on consensus from these interviews by specialty focusing on unique aspects of care, research, and management. We have also defined the Center of Excellence beyond the multidisciplinary clinic.
Conclusion: Establishment of clinics motivates collaboration to provide evidence-based new standards of care, increases the knowledge base including through randomized controlled trials, and offers an additional resource for the community. They have a role in global telemedicine, including to rural areas with few resources, and create opportunities for clinical work to inform basic and translational research. As a care team, we are currently charged with understanding the molecular basis of PWS beyond the known genetic cause; developing appropriate clinical outcome measures and biomarkers; bringing new therapies to change the natural history of disease; improving daily patient struggles, access to care, and caregiver burden; and decreasing healthcare load. Based on experience to date with a PWS multidisciplinary clinic, we propose a design for this approach and emphasize the development of "Centers of Excellence." We highlight the dearth of evidence for management approaches creating huge gaps in care practices as a means to illustrate the importance of the collaborative environment and translational approaches.
Keywords: Prader-Willi syndrome; genomic imprinting; interdisciplinary communication; outcome and process assessment (health care); telemedicine; translational medical research.
© 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
Conflict of interest statement
Dr. Duis consults with Disruptive Nutrition and is a sub‐investigator on clinical trials funded by GLWL and Soleno Pharmaceuticals. Dr. Scheimann completed research funded by Zafgen Pharmaceuticals. Current sources of funding include NIMH and Foundation for Prader‐Willi Research. Dr. Salehi has completed research funded by Zafgen Pharmaceuticals. She is currently working with Soleno Pharmaceuticals. Current sources of funding to Dr. Miller include the Prader‐Willi Syndrome Association USA and the Foundation for Prader‐Willi Research. Dr. Shoemaker has completed research funded by Zafgen Pharmaceuticals and served on their hypothalamic obesity advisory board. She is participating in clinical trials funded by Soleno and GLWL Pharmaceuticals. Current sources of funding to Dr. Shoemaker include AstraZeneca, Novo Nordisk, Rhythm Pharmaceuticals, and NIDDK K23 DK101689. Dr. Miller completed research funded by Zafgen Pharmaceuticals, Ferring Pharmaceuticals, and Rhythm Pharmaceuticals. She is participating in clinical trials funded by Soleno and GLWL Pharmaceuticals. Drs. van Wattum, Bingham and Ms. Brokamp, Ms. Childers, and Ms. Fairbrother report no financial or potential conflict of interests.
Figures
References
-
- Alen, F. , Crespo, I. , Ramirez‐Lopez, M. T. , Jagerovic, N. , Goya, P. , de Fonseca, F. R. , & Orio, L. (2013). Ghrelin‐induced orexigenic effect in rats depends on the metabolic status and is counteracted by peripheral CB1 receptor antagonism. PLoS One, 8(4), e60918 10.1371/journal.pone.0060918 - DOI - PMC - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
